ANNALS OF SURGICAL ONCOLOGY-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=2299148, encodeId=97972299148b7, content=投稿命中率:75.0 偏重的研究方向：泌尿肿瘤 经验分享：返修了两次有机会接收吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3bf98139302, createdName=ms1000000687399320, createdTime=Fri Jan 30 14:28:52 CST 2026, time=2026-01-30, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2282878, encodeId=967322828e897, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：肝癌术后辅助治疗 经验分享：肝癌术后辅助治疗全国多中心回顾性队列研究 3000多样本量机器学习+长随访 8.26正式投稿成功（所有人必须填表格，否则会被退回 9.8 一审返修（一般会配一个专业统计学专家） 9.12修回 9.26接受，刚好历时一个月 整体过程算顺利，文章此前一直在投10+被拒的麻了后，直接转到ASO。ASO每年虽然发文量大，但国人占比不到10%，老牌杂志冲着口碑去的，外科学领域算是还可以的。主要是速度快，着急毕业的可以试一下，一定记得所有作者需要填写利益披露表格，而且所有的邮箱得是对的。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=85, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=40c08137941, createdName=ms7000001452986632, createdTime=Sat Sep 27 09:59:25 CST 2025, time=2025-09-27, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2286418, encodeId=f46322864187c, content=修回去要多久才能有结果啊，10.2修回去了，到现在还在外审，唉, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eda19532546, createdName=ms4000000646376390, createdTime=Mon Oct 27 10:37:29 CST 2025, time=2025-10-27, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2286099, encodeId=dfa22286099c5, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：2025.7.23 投稿 under review 2025.8.4 Forms Completion submitted 2025.8.6 送审 2025.9.11 Major Revision with No Acceptance Implied 2025.9.25 a revision has been submitted 2025.10.22 Accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9f2b1770544, createdName=ms4237561583740228, createdTime=Sat Oct 25 16:29:13 CST 2025, time=2025-10-25, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2283853, encodeId=790c2283853df, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肝癌基础研究 经验分享：请问大家从accept到proof，一般用了多久呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=22788096283, createdName=ms7000001003840724, createdTime=Tue Oct 07 00:36:27 CST 2025, time=2025-10-07, status=1, ipAttribution=台湾省), GetPortalCommentsPageByObjectIdResponse(id=2245357, encodeId=58eb224535ef0, content=请问一下这个杂志第一次决定一般多久啊，显示两个编辑，under review,是不是还没送审, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=89, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fbf19205382, createdName=ms5000000711521518, createdTime=Sat Dec 28 17:51:04 CST 2024, time=2024-12-28, status=1, ipAttribution=新疆), GetPortalCommentsPageByObjectIdResponse(id=2279516, encodeId=4f6e22e9516bf, content=它主要收录各专科外科肿瘤学最新进展的原创文章，像胃肠、乳腺、肝胆、结直肠、胸部肿瘤及转化研究等领域。期刊每月发行，需要找至少2位专家审稿 平均审稿周期约 2.8 个月 投稿前要确保论文内容有创新性，语言规范，格式符合要求 对实验设计、数据呈现等方面也很看重，要严谨清晰 要是能突出研究对临床实践或外科肿瘤学发展的意义，被接收的概率会更高。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms7000002977722171, createdTime=Sun Aug 31 22:31:48 CST 2025, time=2025-08-31, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2259802, encodeId=5d2c225980230, content=求大佬指教！问题①Information Regarding US National Institutes of Health (NIH) Public Access Policy需要操作吗；问题②author reflection要写多少字，具体有什么需要注意的吗；问题③我要选择非oa，在哪一步会给我选择缴费啊。谢谢各路大佬，我一个小白问不到任何人，感谢感谢！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=101, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=59aa8720465, createdName=ms1000000534985624, createdTime=Wed Apr 09 21:42:36 CST 2025, time=2025-04-09, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2274617, encodeId=911c22e4617e2, content=提交后每位作者会收到电子邮件，需要完成利益冲突表格，必须填写，否则会退回, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=74, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=匿名用户, createdTime=Thu Jul 24 10:12:30 CST 2025, time=2025-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2201257, encodeId=d7cf220125e92, content=审稿速度:1.0 | 投稿命中率:95.0 偏重的研究方向：肿瘤外科 经验分享：这个杂志很棒，现在没有审稿费用，我们科很多研究都在这里发表，感觉比ejso快很多, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=169, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dca18435542, createdName=新来的小李, createdTime=Tue Apr 30 14:30:34 CST 2024, time=2024-04-30, status=1, ipAttribution=贵州省)]

2026-01-30 ms1000000687399320 来自湖北省

投稿命中率:75.0
偏重的研究方向：泌尿肿瘤
经验分享：返修了两次有机会接收吗

32 1 举报

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2299148, encodeId=97972299148b7, content=投稿命中率:75.0 偏重的研究方向：泌尿肿瘤 经验分享：返修了两次有机会接收吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3bf98139302, createdName=ms1000000687399320, createdTime=Fri Jan 30 14:28:52 CST 2026, time=2026-01-30, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2282878, encodeId=967322828e897, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：肝癌术后辅助治疗 经验分享：肝癌术后辅助治疗全国多中心回顾性队列研究 3000多样本量机器学习+长随访 8.26正式投稿成功（所有人必须填表格，否则会被退回 9.8 一审返修（一般会配一个专业统计学专家） 9.12修回 9.26接受，刚好历时一个月 整体过程算顺利，文章此前一直在投10+被拒的麻了后，直接转到ASO。ASO每年虽然发文量大，但国人占比不到10%，老牌杂志冲着口碑去的，外科学领域算是还可以的。主要是速度快，着急毕业的可以试一下，一定记得所有作者需要填写利益披露表格，而且所有的邮箱得是对的。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=85, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=40c08137941, createdName=ms7000001452986632, createdTime=Sat Sep 27 09:59:25 CST 2025, time=2025-09-27, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2286418, encodeId=f46322864187c, content=修回去要多久才能有结果啊，10.2修回去了，到现在还在外审，唉, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eda19532546, createdName=ms4000000646376390, createdTime=Mon Oct 27 10:37:29 CST 2025, time=2025-10-27, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2286099, encodeId=dfa22286099c5, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：2025.7.23 投稿 under review 2025.8.4 Forms Completion submitted 2025.8.6 送审 2025.9.11 Major Revision with No Acceptance Implied 2025.9.25 a revision has been submitted 2025.10.22 Accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9f2b1770544, createdName=ms4237561583740228, createdTime=Sat Oct 25 16:29:13 CST 2025, time=2025-10-25, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2283853, encodeId=790c2283853df, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肝癌基础研究 经验分享：请问大家从accept到proof，一般用了多久呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=22788096283, createdName=ms7000001003840724, createdTime=Tue Oct 07 00:36:27 CST 2025, time=2025-10-07, status=1, ipAttribution=台湾省), GetPortalCommentsPageByObjectIdResponse(id=2245357, encodeId=58eb224535ef0, content=请问一下这个杂志第一次决定一般多久啊，显示两个编辑，under review,是不是还没送审, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=89, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fbf19205382, createdName=ms5000000711521518, createdTime=Sat Dec 28 17:51:04 CST 2024, time=2024-12-28, status=1, ipAttribution=新疆), GetPortalCommentsPageByObjectIdResponse(id=2279516, encodeId=4f6e22e9516bf, content=它主要收录各专科外科肿瘤学最新进展的原创文章，像胃肠、乳腺、肝胆、结直肠、胸部肿瘤及转化研究等领域。期刊每月发行，需要找至少2位专家审稿 平均审稿周期约 2.8 个月 投稿前要确保论文内容有创新性，语言规范，格式符合要求 对实验设计、数据呈现等方面也很看重，要严谨清晰 要是能突出研究对临床实践或外科肿瘤学发展的意义，被接收的概率会更高。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms7000002977722171, createdTime=Sun Aug 31 22:31:48 CST 2025, time=2025-08-31, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2259802, encodeId=5d2c225980230, content=求大佬指教！问题①Information Regarding US National Institutes of Health (NIH) Public Access Policy需要操作吗；问题②author reflection要写多少字，具体有什么需要注意的吗；问题③我要选择非oa，在哪一步会给我选择缴费啊。谢谢各路大佬，我一个小白问不到任何人，感谢感谢！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=101, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=59aa8720465, createdName=ms1000000534985624, createdTime=Wed Apr 09 21:42:36 CST 2025, time=2025-04-09, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2274617, encodeId=911c22e4617e2, content=提交后每位作者会收到电子邮件，需要完成利益冲突表格，必须填写，否则会退回, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=74, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=匿名用户, createdTime=Thu Jul 24 10:12:30 CST 2025, time=2025-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2201257, encodeId=d7cf220125e92, content=审稿速度:1.0 | 投稿命中率:95.0 偏重的研究方向：肿瘤外科 经验分享：这个杂志很棒，现在没有审稿费用，我们科很多研究都在这里发表，感觉比ejso快很多, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=169, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dca18435542, createdName=新来的小李, createdTime=Tue Apr 30 14:30:34 CST 2024, time=2024-04-30, status=1, ipAttribution=贵州省)]

2025-09-27 ms7000001452986632 来自湖北省

审稿速度:1.0 | 投稿命中率:50.0
偏重的研究方向：肝癌术后辅助治疗
经验分享：肝癌术后辅助治疗全国多中心回顾性队列研究
3000多样本量机器学习+长随访
8.26正式投稿成功（所有人必须填表格，否则会被退回
9.8 一审返修（一般会配一个专业统计学专家）
9.12修回
9.26接受，刚好历时一个月
整体过程算顺利，文章此前一直在投10+被拒的麻了后，直接转到ASO。ASO每年虽然发文量大，但国人占比不到10%，老牌杂志冲着口碑去的，外科学领域算是还可以的。主要是速度快，着急毕业的可以试一下，一定记得所有作者需要填写利益披露表格，而且所有的邮箱得是对的。

85 2 举报

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=2299148, encodeId=97972299148b7, content=投稿命中率:75.0 偏重的研究方向：泌尿肿瘤 经验分享：返修了两次有机会接收吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3bf98139302, createdName=ms1000000687399320, createdTime=Fri Jan 30 14:28:52 CST 2026, time=2026-01-30, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2282878, encodeId=967322828e897, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：肝癌术后辅助治疗 经验分享：肝癌术后辅助治疗全国多中心回顾性队列研究 3000多样本量机器学习+长随访 8.26正式投稿成功（所有人必须填表格，否则会被退回 9.8 一审返修（一般会配一个专业统计学专家） 9.12修回 9.26接受，刚好历时一个月 整体过程算顺利，文章此前一直在投10+被拒的麻了后，直接转到ASO。ASO每年虽然发文量大，但国人占比不到10%，老牌杂志冲着口碑去的，外科学领域算是还可以的。主要是速度快，着急毕业的可以试一下，一定记得所有作者需要填写利益披露表格，而且所有的邮箱得是对的。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=85, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=40c08137941, createdName=ms7000001452986632, createdTime=Sat Sep 27 09:59:25 CST 2025, time=2025-09-27, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2286418, encodeId=f46322864187c, content=修回去要多久才能有结果啊，10.2修回去了，到现在还在外审，唉, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eda19532546, createdName=ms4000000646376390, createdTime=Mon Oct 27 10:37:29 CST 2025, time=2025-10-27, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2286099, encodeId=dfa22286099c5, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：2025.7.23 投稿 under review 2025.8.4 Forms Completion submitted 2025.8.6 送审 2025.9.11 Major Revision with No Acceptance Implied 2025.9.25 a revision has been submitted 2025.10.22 Accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9f2b1770544, createdName=ms4237561583740228, createdTime=Sat Oct 25 16:29:13 CST 2025, time=2025-10-25, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2283853, encodeId=790c2283853df, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肝癌基础研究 经验分享：请问大家从accept到proof，一般用了多久呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=22788096283, createdName=ms7000001003840724, createdTime=Tue Oct 07 00:36:27 CST 2025, time=2025-10-07, status=1, ipAttribution=台湾省), GetPortalCommentsPageByObjectIdResponse(id=2245357, encodeId=58eb224535ef0, content=请问一下这个杂志第一次决定一般多久啊，显示两个编辑，under review,是不是还没送审, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=89, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fbf19205382, createdName=ms5000000711521518, createdTime=Sat Dec 28 17:51:04 CST 2024, time=2024-12-28, status=1, ipAttribution=新疆), GetPortalCommentsPageByObjectIdResponse(id=2279516, encodeId=4f6e22e9516bf, content=它主要收录各专科外科肿瘤学最新进展的原创文章，像胃肠、乳腺、肝胆、结直肠、胸部肿瘤及转化研究等领域。期刊每月发行，需要找至少2位专家审稿 平均审稿周期约 2.8 个月 投稿前要确保论文内容有创新性，语言规范，格式符合要求 对实验设计、数据呈现等方面也很看重，要严谨清晰 要是能突出研究对临床实践或外科肿瘤学发展的意义，被接收的概率会更高。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms7000002977722171, createdTime=Sun Aug 31 22:31:48 CST 2025, time=2025-08-31, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2259802, encodeId=5d2c225980230, content=求大佬指教！问题①Information Regarding US National Institutes of Health (NIH) Public Access Policy需要操作吗；问题②author reflection要写多少字，具体有什么需要注意的吗；问题③我要选择非oa，在哪一步会给我选择缴费啊。谢谢各路大佬，我一个小白问不到任何人，感谢感谢！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=101, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=59aa8720465, createdName=ms1000000534985624, createdTime=Wed Apr 09 21:42:36 CST 2025, time=2025-04-09, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2274617, encodeId=911c22e4617e2, content=提交后每位作者会收到电子邮件，需要完成利益冲突表格，必须填写，否则会退回, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=74, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=匿名用户, createdTime=Thu Jul 24 10:12:30 CST 2025, time=2025-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2201257, encodeId=d7cf220125e92, content=审稿速度:1.0 | 投稿命中率:95.0 偏重的研究方向：肿瘤外科 经验分享：这个杂志很棒，现在没有审稿费用，我们科很多研究都在这里发表，感觉比ejso快很多, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=169, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dca18435542, createdName=新来的小李, createdTime=Tue Apr 30 14:30:34 CST 2024, time=2024-04-30, status=1, ipAttribution=贵州省)]

2025-10-27 ms4000000646376390 来自北京

修回去要多久才能有结果啊，10.2修回去了，到现在还在外审，唉

44 0 举报

[GetPortalCommentsPageByObjectIdResponse(id=2299148, encodeId=97972299148b7, content=投稿命中率:75.0 偏重的研究方向：泌尿肿瘤 经验分享：返修了两次有机会接收吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3bf98139302, createdName=ms1000000687399320, createdTime=Fri Jan 30 14:28:52 CST 2026, time=2026-01-30, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2282878, encodeId=967322828e897, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：肝癌术后辅助治疗 经验分享：肝癌术后辅助治疗全国多中心回顾性队列研究 3000多样本量机器学习+长随访 8.26正式投稿成功（所有人必须填表格，否则会被退回 9.8 一审返修（一般会配一个专业统计学专家） 9.12修回 9.26接受，刚好历时一个月 整体过程算顺利，文章此前一直在投10+被拒的麻了后，直接转到ASO。ASO每年虽然发文量大，但国人占比不到10%，老牌杂志冲着口碑去的，外科学领域算是还可以的。主要是速度快，着急毕业的可以试一下，一定记得所有作者需要填写利益披露表格，而且所有的邮箱得是对的。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=85, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=40c08137941, createdName=ms7000001452986632, createdTime=Sat Sep 27 09:59:25 CST 2025, time=2025-09-27, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2286418, encodeId=f46322864187c, content=修回去要多久才能有结果啊，10.2修回去了，到现在还在外审，唉, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eda19532546, createdName=ms4000000646376390, createdTime=Mon Oct 27 10:37:29 CST 2025, time=2025-10-27, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2286099, encodeId=dfa22286099c5, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：2025.7.23 投稿 under review 2025.8.4 Forms Completion submitted 2025.8.6 送审 2025.9.11 Major Revision with No Acceptance Implied 2025.9.25 a revision has been submitted 2025.10.22 Accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9f2b1770544, createdName=ms4237561583740228, createdTime=Sat Oct 25 16:29:13 CST 2025, time=2025-10-25, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2283853, encodeId=790c2283853df, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肝癌基础研究 经验分享：请问大家从accept到proof，一般用了多久呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=22788096283, createdName=ms7000001003840724, createdTime=Tue Oct 07 00:36:27 CST 2025, time=2025-10-07, status=1, ipAttribution=台湾省), GetPortalCommentsPageByObjectIdResponse(id=2245357, encodeId=58eb224535ef0, content=请问一下这个杂志第一次决定一般多久啊，显示两个编辑，under review,是不是还没送审, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=89, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fbf19205382, createdName=ms5000000711521518, createdTime=Sat Dec 28 17:51:04 CST 2024, time=2024-12-28, status=1, ipAttribution=新疆), GetPortalCommentsPageByObjectIdResponse(id=2279516, encodeId=4f6e22e9516bf, content=它主要收录各专科外科肿瘤学最新进展的原创文章，像胃肠、乳腺、肝胆、结直肠、胸部肿瘤及转化研究等领域。期刊每月发行，需要找至少2位专家审稿 平均审稿周期约 2.8 个月 投稿前要确保论文内容有创新性，语言规范，格式符合要求 对实验设计、数据呈现等方面也很看重，要严谨清晰 要是能突出研究对临床实践或外科肿瘤学发展的意义，被接收的概率会更高。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms7000002977722171, createdTime=Sun Aug 31 22:31:48 CST 2025, time=2025-08-31, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2259802, encodeId=5d2c225980230, content=求大佬指教！问题①Information Regarding US National Institutes of Health (NIH) Public Access Policy需要操作吗；问题②author reflection要写多少字，具体有什么需要注意的吗；问题③我要选择非oa，在哪一步会给我选择缴费啊。谢谢各路大佬，我一个小白问不到任何人，感谢感谢！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=101, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=59aa8720465, createdName=ms1000000534985624, createdTime=Wed Apr 09 21:42:36 CST 2025, time=2025-04-09, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2274617, encodeId=911c22e4617e2, content=提交后每位作者会收到电子邮件，需要完成利益冲突表格，必须填写，否则会退回, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=74, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=匿名用户, createdTime=Thu Jul 24 10:12:30 CST 2025, time=2025-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2201257, encodeId=d7cf220125e92, content=审稿速度:1.0 | 投稿命中率:95.0 偏重的研究方向：肿瘤外科 经验分享：这个杂志很棒，现在没有审稿费用，我们科很多研究都在这里发表，感觉比ejso快很多, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=169, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dca18435542, createdName=新来的小李, createdTime=Tue Apr 30 14:30:34 CST 2024, time=2024-04-30, status=1, ipAttribution=贵州省)]

2025-10-25 ms4237561583740228 来自浙江省

审稿速度:3.0 | 投稿命中率:50.0
经验分享：2025.7.23 投稿 under review
2025.8.4 Forms Completion submitted
2025.8.6 送审
2025.9.11 Major Revision with No Acceptance Implied
2025.9.25 a revision has been submitted
2025.10.22 Accept

54 0 举报

[GetPortalCommentsPageByObjectIdResponse(id=2299148, encodeId=97972299148b7, content=投稿命中率:75.0 偏重的研究方向：泌尿肿瘤 经验分享：返修了两次有机会接收吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3bf98139302, createdName=ms1000000687399320, createdTime=Fri Jan 30 14:28:52 CST 2026, time=2026-01-30, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2282878, encodeId=967322828e897, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：肝癌术后辅助治疗 经验分享：肝癌术后辅助治疗全国多中心回顾性队列研究 3000多样本量机器学习+长随访 8.26正式投稿成功（所有人必须填表格，否则会被退回 9.8 一审返修（一般会配一个专业统计学专家） 9.12修回 9.26接受，刚好历时一个月 整体过程算顺利，文章此前一直在投10+被拒的麻了后，直接转到ASO。ASO每年虽然发文量大，但国人占比不到10%，老牌杂志冲着口碑去的，外科学领域算是还可以的。主要是速度快，着急毕业的可以试一下，一定记得所有作者需要填写利益披露表格，而且所有的邮箱得是对的。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=85, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=40c08137941, createdName=ms7000001452986632, createdTime=Sat Sep 27 09:59:25 CST 2025, time=2025-09-27, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2286418, encodeId=f46322864187c, content=修回去要多久才能有结果啊，10.2修回去了，到现在还在外审，唉, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eda19532546, createdName=ms4000000646376390, createdTime=Mon Oct 27 10:37:29 CST 2025, time=2025-10-27, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2286099, encodeId=dfa22286099c5, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：2025.7.23 投稿 under review 2025.8.4 Forms Completion submitted 2025.8.6 送审 2025.9.11 Major Revision with No Acceptance Implied 2025.9.25 a revision has been submitted 2025.10.22 Accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9f2b1770544, createdName=ms4237561583740228, createdTime=Sat Oct 25 16:29:13 CST 2025, time=2025-10-25, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2283853, encodeId=790c2283853df, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肝癌基础研究 经验分享：请问大家从accept到proof，一般用了多久呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=22788096283, createdName=ms7000001003840724, createdTime=Tue Oct 07 00:36:27 CST 2025, time=2025-10-07, status=1, ipAttribution=台湾省), GetPortalCommentsPageByObjectIdResponse(id=2245357, encodeId=58eb224535ef0, content=请问一下这个杂志第一次决定一般多久啊，显示两个编辑，under review,是不是还没送审, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=89, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fbf19205382, createdName=ms5000000711521518, createdTime=Sat Dec 28 17:51:04 CST 2024, time=2024-12-28, status=1, ipAttribution=新疆), GetPortalCommentsPageByObjectIdResponse(id=2279516, encodeId=4f6e22e9516bf, content=它主要收录各专科外科肿瘤学最新进展的原创文章，像胃肠、乳腺、肝胆、结直肠、胸部肿瘤及转化研究等领域。期刊每月发行，需要找至少2位专家审稿 平均审稿周期约 2.8 个月 投稿前要确保论文内容有创新性，语言规范，格式符合要求 对实验设计、数据呈现等方面也很看重，要严谨清晰 要是能突出研究对临床实践或外科肿瘤学发展的意义，被接收的概率会更高。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms7000002977722171, createdTime=Sun Aug 31 22:31:48 CST 2025, time=2025-08-31, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2259802, encodeId=5d2c225980230, content=求大佬指教！问题①Information Regarding US National Institutes of Health (NIH) Public Access Policy需要操作吗；问题②author reflection要写多少字，具体有什么需要注意的吗；问题③我要选择非oa，在哪一步会给我选择缴费啊。谢谢各路大佬，我一个小白问不到任何人，感谢感谢！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=101, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=59aa8720465, createdName=ms1000000534985624, createdTime=Wed Apr 09 21:42:36 CST 2025, time=2025-04-09, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2274617, encodeId=911c22e4617e2, content=提交后每位作者会收到电子邮件，需要完成利益冲突表格，必须填写，否则会退回, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=74, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=匿名用户, createdTime=Thu Jul 24 10:12:30 CST 2025, time=2025-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2201257, encodeId=d7cf220125e92, content=审稿速度:1.0 | 投稿命中率:95.0 偏重的研究方向：肿瘤外科 经验分享：这个杂志很棒，现在没有审稿费用，我们科很多研究都在这里发表，感觉比ejso快很多, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=169, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dca18435542, createdName=新来的小李, createdTime=Tue Apr 30 14:30:34 CST 2024, time=2024-04-30, status=1, ipAttribution=贵州省)]

2025-10-07 ms7000001003840724 来自台湾省

审稿速度:2.0 | 投稿命中率:50.0
偏重的研究方向：肝癌基础研究
经验分享：请问大家从accept到proof，一般用了多久呀

78 0 举报

[GetPortalCommentsPageByObjectIdResponse(id=2299148, encodeId=97972299148b7, content=投稿命中率:75.0 偏重的研究方向：泌尿肿瘤 经验分享：返修了两次有机会接收吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3bf98139302, createdName=ms1000000687399320, createdTime=Fri Jan 30 14:28:52 CST 2026, time=2026-01-30, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2282878, encodeId=967322828e897, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：肝癌术后辅助治疗 经验分享：肝癌术后辅助治疗全国多中心回顾性队列研究 3000多样本量机器学习+长随访 8.26正式投稿成功（所有人必须填表格，否则会被退回 9.8 一审返修（一般会配一个专业统计学专家） 9.12修回 9.26接受，刚好历时一个月 整体过程算顺利，文章此前一直在投10+被拒的麻了后，直接转到ASO。ASO每年虽然发文量大，但国人占比不到10%，老牌杂志冲着口碑去的，外科学领域算是还可以的。主要是速度快，着急毕业的可以试一下，一定记得所有作者需要填写利益披露表格，而且所有的邮箱得是对的。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=85, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=40c08137941, createdName=ms7000001452986632, createdTime=Sat Sep 27 09:59:25 CST 2025, time=2025-09-27, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2286418, encodeId=f46322864187c, content=修回去要多久才能有结果啊，10.2修回去了，到现在还在外审，唉, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eda19532546, createdName=ms4000000646376390, createdTime=Mon Oct 27 10:37:29 CST 2025, time=2025-10-27, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2286099, encodeId=dfa22286099c5, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：2025.7.23 投稿 under review 2025.8.4 Forms Completion submitted 2025.8.6 送审 2025.9.11 Major Revision with No Acceptance Implied 2025.9.25 a revision has been submitted 2025.10.22 Accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9f2b1770544, createdName=ms4237561583740228, createdTime=Sat Oct 25 16:29:13 CST 2025, time=2025-10-25, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2283853, encodeId=790c2283853df, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肝癌基础研究 经验分享：请问大家从accept到proof，一般用了多久呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=22788096283, createdName=ms7000001003840724, createdTime=Tue Oct 07 00:36:27 CST 2025, time=2025-10-07, status=1, ipAttribution=台湾省), GetPortalCommentsPageByObjectIdResponse(id=2245357, encodeId=58eb224535ef0, content=请问一下这个杂志第一次决定一般多久啊，显示两个编辑，under review,是不是还没送审, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=89, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fbf19205382, createdName=ms5000000711521518, createdTime=Sat Dec 28 17:51:04 CST 2024, time=2024-12-28, status=1, ipAttribution=新疆), GetPortalCommentsPageByObjectIdResponse(id=2279516, encodeId=4f6e22e9516bf, content=它主要收录各专科外科肿瘤学最新进展的原创文章，像胃肠、乳腺、肝胆、结直肠、胸部肿瘤及转化研究等领域。期刊每月发行，需要找至少2位专家审稿 平均审稿周期约 2.8 个月 投稿前要确保论文内容有创新性，语言规范，格式符合要求 对实验设计、数据呈现等方面也很看重，要严谨清晰 要是能突出研究对临床实践或外科肿瘤学发展的意义，被接收的概率会更高。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms7000002977722171, createdTime=Sun Aug 31 22:31:48 CST 2025, time=2025-08-31, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2259802, encodeId=5d2c225980230, content=求大佬指教！问题①Information Regarding US National Institutes of Health (NIH) Public Access Policy需要操作吗；问题②author reflection要写多少字，具体有什么需要注意的吗；问题③我要选择非oa，在哪一步会给我选择缴费啊。谢谢各路大佬，我一个小白问不到任何人，感谢感谢！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=101, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=59aa8720465, createdName=ms1000000534985624, createdTime=Wed Apr 09 21:42:36 CST 2025, time=2025-04-09, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2274617, encodeId=911c22e4617e2, content=提交后每位作者会收到电子邮件，需要完成利益冲突表格，必须填写，否则会退回, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=74, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=匿名用户, createdTime=Thu Jul 24 10:12:30 CST 2025, time=2025-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2201257, encodeId=d7cf220125e92, content=审稿速度:1.0 | 投稿命中率:95.0 偏重的研究方向：肿瘤外科 经验分享：这个杂志很棒，现在没有审稿费用，我们科很多研究都在这里发表，感觉比ejso快很多, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=169, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dca18435542, createdName=新来的小李, createdTime=Tue Apr 30 14:30:34 CST 2024, time=2024-04-30, status=1, ipAttribution=贵州省)]

2024-12-28 ms5000000711521518 来自新疆

请问一下这个杂志第一次决定一般多久啊，显示两个编辑，under review,是不是还没送审

89 3 举报

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=2299148, encodeId=97972299148b7, content=投稿命中率:75.0 偏重的研究方向：泌尿肿瘤 经验分享：返修了两次有机会接收吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3bf98139302, createdName=ms1000000687399320, createdTime=Fri Jan 30 14:28:52 CST 2026, time=2026-01-30, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2282878, encodeId=967322828e897, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：肝癌术后辅助治疗 经验分享：肝癌术后辅助治疗全国多中心回顾性队列研究 3000多样本量机器学习+长随访 8.26正式投稿成功（所有人必须填表格，否则会被退回 9.8 一审返修（一般会配一个专业统计学专家） 9.12修回 9.26接受，刚好历时一个月 整体过程算顺利，文章此前一直在投10+被拒的麻了后，直接转到ASO。ASO每年虽然发文量大，但国人占比不到10%，老牌杂志冲着口碑去的，外科学领域算是还可以的。主要是速度快，着急毕业的可以试一下，一定记得所有作者需要填写利益披露表格，而且所有的邮箱得是对的。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=85, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=40c08137941, createdName=ms7000001452986632, createdTime=Sat Sep 27 09:59:25 CST 2025, time=2025-09-27, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2286418, encodeId=f46322864187c, content=修回去要多久才能有结果啊，10.2修回去了，到现在还在外审，唉, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eda19532546, createdName=ms4000000646376390, createdTime=Mon Oct 27 10:37:29 CST 2025, time=2025-10-27, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2286099, encodeId=dfa22286099c5, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：2025.7.23 投稿 under review 2025.8.4 Forms Completion submitted 2025.8.6 送审 2025.9.11 Major Revision with No Acceptance Implied 2025.9.25 a revision has been submitted 2025.10.22 Accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9f2b1770544, createdName=ms4237561583740228, createdTime=Sat Oct 25 16:29:13 CST 2025, time=2025-10-25, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2283853, encodeId=790c2283853df, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肝癌基础研究 经验分享：请问大家从accept到proof，一般用了多久呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=22788096283, createdName=ms7000001003840724, createdTime=Tue Oct 07 00:36:27 CST 2025, time=2025-10-07, status=1, ipAttribution=台湾省), GetPortalCommentsPageByObjectIdResponse(id=2245357, encodeId=58eb224535ef0, content=请问一下这个杂志第一次决定一般多久啊，显示两个编辑，under review,是不是还没送审, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=89, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fbf19205382, createdName=ms5000000711521518, createdTime=Sat Dec 28 17:51:04 CST 2024, time=2024-12-28, status=1, ipAttribution=新疆), GetPortalCommentsPageByObjectIdResponse(id=2279516, encodeId=4f6e22e9516bf, content=它主要收录各专科外科肿瘤学最新进展的原创文章，像胃肠、乳腺、肝胆、结直肠、胸部肿瘤及转化研究等领域。期刊每月发行，需要找至少2位专家审稿 平均审稿周期约 2.8 个月 投稿前要确保论文内容有创新性，语言规范，格式符合要求 对实验设计、数据呈现等方面也很看重，要严谨清晰 要是能突出研究对临床实践或外科肿瘤学发展的意义，被接收的概率会更高。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms7000002977722171, createdTime=Sun Aug 31 22:31:48 CST 2025, time=2025-08-31, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2259802, encodeId=5d2c225980230, content=求大佬指教！问题①Information Regarding US National Institutes of Health (NIH) Public Access Policy需要操作吗；问题②author reflection要写多少字，具体有什么需要注意的吗；问题③我要选择非oa，在哪一步会给我选择缴费啊。谢谢各路大佬，我一个小白问不到任何人，感谢感谢！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=101, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=59aa8720465, createdName=ms1000000534985624, createdTime=Wed Apr 09 21:42:36 CST 2025, time=2025-04-09, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2274617, encodeId=911c22e4617e2, content=提交后每位作者会收到电子邮件，需要完成利益冲突表格，必须填写，否则会退回, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=74, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=匿名用户, createdTime=Thu Jul 24 10:12:30 CST 2025, time=2025-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2201257, encodeId=d7cf220125e92, content=审稿速度:1.0 | 投稿命中率:95.0 偏重的研究方向：肿瘤外科 经验分享：这个杂志很棒，现在没有审稿费用，我们科很多研究都在这里发表，感觉比ejso快很多, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=169, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dca18435542, createdName=新来的小李, createdTime=Tue Apr 30 14:30:34 CST 2024, time=2024-04-30, status=1, ipAttribution=贵州省)]

2025-08-31 ms7000002977722171 来自上海

它主要收录各专科外科肿瘤学最新进展的原创文章，像胃肠、乳腺、肝胆、结直肠、胸部肿瘤及转化研究等领域。期刊每月发行，需要找至少2位专家审稿
平均审稿周期约 2.8 个月
投稿前要确保论文内容有创新性，语言规范，格式符合要求
对实验设计、数据呈现等方面也很看重，要严谨清晰
要是能突出研究对临床实践或外科肿瘤学发展的意义，被接收的概率会更高。

77 0 举报

[GetPortalCommentsPageByObjectIdResponse(id=2299148, encodeId=97972299148b7, content=投稿命中率:75.0 偏重的研究方向：泌尿肿瘤 经验分享：返修了两次有机会接收吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3bf98139302, createdName=ms1000000687399320, createdTime=Fri Jan 30 14:28:52 CST 2026, time=2026-01-30, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2282878, encodeId=967322828e897, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：肝癌术后辅助治疗 经验分享：肝癌术后辅助治疗全国多中心回顾性队列研究 3000多样本量机器学习+长随访 8.26正式投稿成功（所有人必须填表格，否则会被退回 9.8 一审返修（一般会配一个专业统计学专家） 9.12修回 9.26接受，刚好历时一个月 整体过程算顺利，文章此前一直在投10+被拒的麻了后，直接转到ASO。ASO每年虽然发文量大，但国人占比不到10%，老牌杂志冲着口碑去的，外科学领域算是还可以的。主要是速度快，着急毕业的可以试一下，一定记得所有作者需要填写利益披露表格，而且所有的邮箱得是对的。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=85, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=40c08137941, createdName=ms7000001452986632, createdTime=Sat Sep 27 09:59:25 CST 2025, time=2025-09-27, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2286418, encodeId=f46322864187c, content=修回去要多久才能有结果啊，10.2修回去了，到现在还在外审，唉, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eda19532546, createdName=ms4000000646376390, createdTime=Mon Oct 27 10:37:29 CST 2025, time=2025-10-27, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2286099, encodeId=dfa22286099c5, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：2025.7.23 投稿 under review 2025.8.4 Forms Completion submitted 2025.8.6 送审 2025.9.11 Major Revision with No Acceptance Implied 2025.9.25 a revision has been submitted 2025.10.22 Accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9f2b1770544, createdName=ms4237561583740228, createdTime=Sat Oct 25 16:29:13 CST 2025, time=2025-10-25, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2283853, encodeId=790c2283853df, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肝癌基础研究 经验分享：请问大家从accept到proof，一般用了多久呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=22788096283, createdName=ms7000001003840724, createdTime=Tue Oct 07 00:36:27 CST 2025, time=2025-10-07, status=1, ipAttribution=台湾省), GetPortalCommentsPageByObjectIdResponse(id=2245357, encodeId=58eb224535ef0, content=请问一下这个杂志第一次决定一般多久啊，显示两个编辑，under review,是不是还没送审, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=89, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fbf19205382, createdName=ms5000000711521518, createdTime=Sat Dec 28 17:51:04 CST 2024, time=2024-12-28, status=1, ipAttribution=新疆), GetPortalCommentsPageByObjectIdResponse(id=2279516, encodeId=4f6e22e9516bf, content=它主要收录各专科外科肿瘤学最新进展的原创文章，像胃肠、乳腺、肝胆、结直肠、胸部肿瘤及转化研究等领域。期刊每月发行，需要找至少2位专家审稿 平均审稿周期约 2.8 个月 投稿前要确保论文内容有创新性，语言规范，格式符合要求 对实验设计、数据呈现等方面也很看重，要严谨清晰 要是能突出研究对临床实践或外科肿瘤学发展的意义，被接收的概率会更高。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms7000002977722171, createdTime=Sun Aug 31 22:31:48 CST 2025, time=2025-08-31, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2259802, encodeId=5d2c225980230, content=求大佬指教！问题①Information Regarding US National Institutes of Health (NIH) Public Access Policy需要操作吗；问题②author reflection要写多少字，具体有什么需要注意的吗；问题③我要选择非oa，在哪一步会给我选择缴费啊。谢谢各路大佬，我一个小白问不到任何人，感谢感谢！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=101, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=59aa8720465, createdName=ms1000000534985624, createdTime=Wed Apr 09 21:42:36 CST 2025, time=2025-04-09, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2274617, encodeId=911c22e4617e2, content=提交后每位作者会收到电子邮件，需要完成利益冲突表格，必须填写，否则会退回, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=74, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=匿名用户, createdTime=Thu Jul 24 10:12:30 CST 2025, time=2025-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2201257, encodeId=d7cf220125e92, content=审稿速度:1.0 | 投稿命中率:95.0 偏重的研究方向：肿瘤外科 经验分享：这个杂志很棒，现在没有审稿费用，我们科很多研究都在这里发表，感觉比ejso快很多, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=169, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dca18435542, createdName=新来的小李, createdTime=Tue Apr 30 14:30:34 CST 2024, time=2024-04-30, status=1, ipAttribution=贵州省)]

2025-04-09 ms1000000534985624 来自江苏省

求大佬指教！问题①Information Regarding US National Institutes of Health (NIH) Public Access Policy需要操作吗；问题②author reflection要写多少字，具体有什么需要注意的吗；问题③我要选择非oa，在哪一步会给我选择缴费啊。谢谢各路大佬，我一个小白问不到任何人，感谢感谢！

101 2 举报

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=2299148, encodeId=97972299148b7, content=投稿命中率:75.0 偏重的研究方向：泌尿肿瘤 经验分享：返修了两次有机会接收吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3bf98139302, createdName=ms1000000687399320, createdTime=Fri Jan 30 14:28:52 CST 2026, time=2026-01-30, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2282878, encodeId=967322828e897, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：肝癌术后辅助治疗 经验分享：肝癌术后辅助治疗全国多中心回顾性队列研究 3000多样本量机器学习+长随访 8.26正式投稿成功（所有人必须填表格，否则会被退回 9.8 一审返修（一般会配一个专业统计学专家） 9.12修回 9.26接受，刚好历时一个月 整体过程算顺利，文章此前一直在投10+被拒的麻了后，直接转到ASO。ASO每年虽然发文量大，但国人占比不到10%，老牌杂志冲着口碑去的，外科学领域算是还可以的。主要是速度快，着急毕业的可以试一下，一定记得所有作者需要填写利益披露表格，而且所有的邮箱得是对的。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=85, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=40c08137941, createdName=ms7000001452986632, createdTime=Sat Sep 27 09:59:25 CST 2025, time=2025-09-27, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2286418, encodeId=f46322864187c, content=修回去要多久才能有结果啊，10.2修回去了，到现在还在外审，唉, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eda19532546, createdName=ms4000000646376390, createdTime=Mon Oct 27 10:37:29 CST 2025, time=2025-10-27, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2286099, encodeId=dfa22286099c5, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：2025.7.23 投稿 under review 2025.8.4 Forms Completion submitted 2025.8.6 送审 2025.9.11 Major Revision with No Acceptance Implied 2025.9.25 a revision has been submitted 2025.10.22 Accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9f2b1770544, createdName=ms4237561583740228, createdTime=Sat Oct 25 16:29:13 CST 2025, time=2025-10-25, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2283853, encodeId=790c2283853df, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肝癌基础研究 经验分享：请问大家从accept到proof，一般用了多久呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=22788096283, createdName=ms7000001003840724, createdTime=Tue Oct 07 00:36:27 CST 2025, time=2025-10-07, status=1, ipAttribution=台湾省), GetPortalCommentsPageByObjectIdResponse(id=2245357, encodeId=58eb224535ef0, content=请问一下这个杂志第一次决定一般多久啊，显示两个编辑，under review,是不是还没送审, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=89, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fbf19205382, createdName=ms5000000711521518, createdTime=Sat Dec 28 17:51:04 CST 2024, time=2024-12-28, status=1, ipAttribution=新疆), GetPortalCommentsPageByObjectIdResponse(id=2279516, encodeId=4f6e22e9516bf, content=它主要收录各专科外科肿瘤学最新进展的原创文章，像胃肠、乳腺、肝胆、结直肠、胸部肿瘤及转化研究等领域。期刊每月发行，需要找至少2位专家审稿 平均审稿周期约 2.8 个月 投稿前要确保论文内容有创新性，语言规范，格式符合要求 对实验设计、数据呈现等方面也很看重，要严谨清晰 要是能突出研究对临床实践或外科肿瘤学发展的意义，被接收的概率会更高。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms7000002977722171, createdTime=Sun Aug 31 22:31:48 CST 2025, time=2025-08-31, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2259802, encodeId=5d2c225980230, content=求大佬指教！问题①Information Regarding US National Institutes of Health (NIH) Public Access Policy需要操作吗；问题②author reflection要写多少字，具体有什么需要注意的吗；问题③我要选择非oa，在哪一步会给我选择缴费啊。谢谢各路大佬，我一个小白问不到任何人，感谢感谢！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=101, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=59aa8720465, createdName=ms1000000534985624, createdTime=Wed Apr 09 21:42:36 CST 2025, time=2025-04-09, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2274617, encodeId=911c22e4617e2, content=提交后每位作者会收到电子邮件，需要完成利益冲突表格，必须填写，否则会退回, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=74, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=匿名用户, createdTime=Thu Jul 24 10:12:30 CST 2025, time=2025-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2201257, encodeId=d7cf220125e92, content=审稿速度:1.0 | 投稿命中率:95.0 偏重的研究方向：肿瘤外科 经验分享：这个杂志很棒，现在没有审稿费用，我们科很多研究都在这里发表，感觉比ejso快很多, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=169, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dca18435542, createdName=新来的小李, createdTime=Tue Apr 30 14:30:34 CST 2024, time=2024-04-30, status=1, ipAttribution=贵州省)]

2025-07-24 匿名用户

提交后每位作者会收到电子邮件，需要完成利益冲突表格，必须填写，否则会退回

74 1 举报

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2299148, encodeId=97972299148b7, content=投稿命中率:75.0 偏重的研究方向：泌尿肿瘤 经验分享：返修了两次有机会接收吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3bf98139302, createdName=ms1000000687399320, createdTime=Fri Jan 30 14:28:52 CST 2026, time=2026-01-30, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2282878, encodeId=967322828e897, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：肝癌术后辅助治疗 经验分享：肝癌术后辅助治疗全国多中心回顾性队列研究 3000多样本量机器学习+长随访 8.26正式投稿成功（所有人必须填表格，否则会被退回 9.8 一审返修（一般会配一个专业统计学专家） 9.12修回 9.26接受，刚好历时一个月 整体过程算顺利，文章此前一直在投10+被拒的麻了后，直接转到ASO。ASO每年虽然发文量大，但国人占比不到10%，老牌杂志冲着口碑去的，外科学领域算是还可以的。主要是速度快，着急毕业的可以试一下，一定记得所有作者需要填写利益披露表格，而且所有的邮箱得是对的。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=85, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=40c08137941, createdName=ms7000001452986632, createdTime=Sat Sep 27 09:59:25 CST 2025, time=2025-09-27, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2286418, encodeId=f46322864187c, content=修回去要多久才能有结果啊，10.2修回去了，到现在还在外审，唉, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eda19532546, createdName=ms4000000646376390, createdTime=Mon Oct 27 10:37:29 CST 2025, time=2025-10-27, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2286099, encodeId=dfa22286099c5, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：2025.7.23 投稿 under review 2025.8.4 Forms Completion submitted 2025.8.6 送审 2025.9.11 Major Revision with No Acceptance Implied 2025.9.25 a revision has been submitted 2025.10.22 Accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9f2b1770544, createdName=ms4237561583740228, createdTime=Sat Oct 25 16:29:13 CST 2025, time=2025-10-25, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2283853, encodeId=790c2283853df, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肝癌基础研究 经验分享：请问大家从accept到proof，一般用了多久呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=22788096283, createdName=ms7000001003840724, createdTime=Tue Oct 07 00:36:27 CST 2025, time=2025-10-07, status=1, ipAttribution=台湾省), GetPortalCommentsPageByObjectIdResponse(id=2245357, encodeId=58eb224535ef0, content=请问一下这个杂志第一次决定一般多久啊，显示两个编辑，under review,是不是还没送审, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=89, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fbf19205382, createdName=ms5000000711521518, createdTime=Sat Dec 28 17:51:04 CST 2024, time=2024-12-28, status=1, ipAttribution=新疆), GetPortalCommentsPageByObjectIdResponse(id=2279516, encodeId=4f6e22e9516bf, content=它主要收录各专科外科肿瘤学最新进展的原创文章，像胃肠、乳腺、肝胆、结直肠、胸部肿瘤及转化研究等领域。期刊每月发行，需要找至少2位专家审稿 平均审稿周期约 2.8 个月 投稿前要确保论文内容有创新性，语言规范，格式符合要求 对实验设计、数据呈现等方面也很看重，要严谨清晰 要是能突出研究对临床实践或外科肿瘤学发展的意义，被接收的概率会更高。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms7000002977722171, createdTime=Sun Aug 31 22:31:48 CST 2025, time=2025-08-31, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2259802, encodeId=5d2c225980230, content=求大佬指教！问题①Information Regarding US National Institutes of Health (NIH) Public Access Policy需要操作吗；问题②author reflection要写多少字，具体有什么需要注意的吗；问题③我要选择非oa，在哪一步会给我选择缴费啊。谢谢各路大佬，我一个小白问不到任何人，感谢感谢！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=101, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=59aa8720465, createdName=ms1000000534985624, createdTime=Wed Apr 09 21:42:36 CST 2025, time=2025-04-09, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2274617, encodeId=911c22e4617e2, content=提交后每位作者会收到电子邮件，需要完成利益冲突表格，必须填写，否则会退回, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=74, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=匿名用户, createdTime=Thu Jul 24 10:12:30 CST 2025, time=2025-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2201257, encodeId=d7cf220125e92, content=审稿速度:1.0 | 投稿命中率:95.0 偏重的研究方向：肿瘤外科 经验分享：这个杂志很棒，现在没有审稿费用，我们科很多研究都在这里发表，感觉比ejso快很多, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=169, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dca18435542, createdName=新来的小李, createdTime=Tue Apr 30 14:30:34 CST 2024, time=2024-04-30, status=1, ipAttribution=贵州省)]

2024-04-30 新来的小李来自贵州省

审稿速度:1.0 | 投稿命中率:95.0
偏重的研究方向：肿瘤外科
经验分享：这个杂志很棒，现在没有审稿费用，我们科很多研究都在这里发表，感觉比ejso快很多

169 9 举报

展开9条回复

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务